Buscar Company Announces That It Will Be Attending

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Buscar Company Announces That It Will Be Attending Keeneland November Auction to Begin Building Out Its Breeding Operations.

MARINA DEL REY, CA, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Buscar Company (OTC: CGLD) announced today that the Company will be attending the November Keeneland auction.  The Company will be looking to acquire weanlings and mares.  The auction will take place November 8-20 in Lexington, Kentucky.  The 4,763 entries in this year’s auction make it the largest edition of the November sale since 2008. It also marks a 6 percent increase in offerings from last year’s auction, which cataloged 4,476.  The November sale has become an increasingly popular destination for trade of elite weanlings. This is best evidenced by the North American record price for a weanling at public auction being surpassed at each of the past two editions of the Keeneland November sale. Keeneland will provide live gavel-to-gavel coverage of the entire auction at www. Keeneland.com .

The Company will be acquiring the weanlings with the intent of reselling them at the Keeneland September Yearling sale in 2017.  This is referred to a s pinhooking. The Company is also looking at acquiring mare to begin studding them in February or March.  The Company invites any shareholder to attend and spend the day with our management team and our amazing bloodstock agents. 

About Buscar Company.   The Company is engaged in the buying, selling and racing of thoroughbreds.  The Company’s focus is acquiring thoroughbreds that can race in the allowance and stakes level of thoroughbred racing; however, the Company will initially begin acquiring thoroughbreds in the claiming level of thoroughbred racing.  More information can be found at  www.buscarcompany.com

Notice Regarding Forward-Looking Statements  in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate.

Contact: Buscar Company info@buscarcompany.com (661) 418-7842

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

OnTime's Bold Vision: Transforming Home Healthcare Admin

Updated Category News Views 7

Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...

Continue Reading
Image Analysis Group Unveils DYNAMIKA V.7 for Clinical Trials

Updated Category News Views 185

Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....

Continue Reading
Sanofi's Strategic Move to Enhance Adult Vaccination Pipeline

Updated Category News Views 95

Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...

Continue Reading
Miral Impact Fund: A New Era for Community and Environment

Updated Category News Views 135

Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...

Continue Reading
Class Action Update for Regeneron Pharmaceuticals Investors

Updated Category News Views 125

Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...

Continue Reading